Desk of Senator Boquist

Geert Vanden Bossche, PhD, DVM

Independent Researcher

Mar 2018 - Present

Managing Director
VARECO
Sep 2012 - 2019
Europe

Independent vaccine consultant with a long- standing track record in Academia, Vaccine Industry and Global Health (GH); providing support on vaccine project management as well as advice, guidance and expert opinion on preclinical development of vaccines & biologicals, from project selection up to IND. Assignments include prophylactic and therapeutic vaccine projects in Human and Veterinary Vaccine Industry, Small Biotech, Global Health organizations in the US or Europe

Head of the Vaccine Development Office
German Centre for Infection Research (DZIF)
Aug 2017 - Dec 2017
Cologne, Germany

Spearheading a portfolio of translational vaccine research projects, conducted at German universities and research centres sponsored by DZIF. Holding overall accountability for strategic alignment of translational infection research in support of preclinical and early clinical testing. Developing a trans-academic translational network for Vaccine development totaling eight universities and research organizations across Germany.

Chief Innovation & Scientific Officer
Univac
Nov 2014 - Nov 2016
Huldenberg

II founded Univac as inventor of a new vaccine technology which I subsequently further developed as CSO of the Company. The technology enables the development of universal vaccines educating the host immune system to redirect immune targeting away from canonical antigens to a widely divergent spectrum of vitally vulnerable pathogen-derived 'self-mimicking' antigens, irrespective of MHC polymorphism. Although 'non-self' and exposed on the surface of infected or pathologically altered cells…

Program Manager

Global Alliance for Vaccines and Immunization (GAVI)
Mar 2015 - Mar 2016
Geneva Area, Switzerland

During my term at GAVI, I coordinated GAVI's Ebola Vaccine Program and contributed to the implementation of an integrated vaccine work plan in collaboration with Global Health Partners (WHO, Bill & Melinda Gates Foundation, CDC, UNICEF), regulators (FDA) and vaccine manufacturers to enable timely deployment or stockpiling of Ebola vaccine candidate(s) that suitably meet the requirements for use in an Ebola epidemic. In this capacity, I also contributed to several workshops aimed at proposing…
Show more

DVM, PhD, adjunct professor

Positions in Academia
Sep 1980 - Sep 2015
Belgium - Germany

- Training in Veterinary Medicine at the faculty Notre-Dame-de-la-Paix and the State University of
Ghent (1980-1983)
- Doctoral degree in Veterinary Medicine from State University of Ghent (1983)
- Postdoctoral training in Equine Medicine and Surgery at the Free University of Berlin, Germany
(1984-1987)
- Postdoctoral Fellowship in Virology at James A. Baker Institute for Animal Health, Cornell
University, Ithaca, NY 14850, USA (Sept 1990- mid 1991)
- Research…
Show more

Senior Program Officer, Global Health, Vaccine Discovery

Bill & Melinda Gates Foundation (BMGF)
May 2008 - Jun 2011
Seattle, Washington 98102, USA

Responsible for operating Vaccine Programs (e.g., HIV-1, Malaria, TB, Polio...) and establishing international product development partnerships for immune interventions in Global Health (e.g., with Academia, Biotech Industry, NIH, Welcome Trust, WHO, PATH). Coordinating and spearheading international collaborations and consortia on innovative vaccine approaches and steering multidisciplinary vaccine initiatives

Global Project Director Influenza Vaccines

Solvay Biologicals
Jul 2007 - May 2008
Weesp, the Netherlands

Responsible for leading the operational aspects of an interdisciplinary project team including the planning and implementation of adjuvanted Influenza vaccines that enable dose sparing. Implementation of commercial-scale production of cell-based methods and expansion of Influenza vaccine production capacity such as to meet DHSS (U.S. Department of Human Health Services) contractual requirements (Pandemic Influenza Preparedness Plan)

Director, Research Program Leader and Head of Adjuvants

Novartis Vaccines & Diagnostics
Aug 2006 - Jul 2007
Siena, Italy & Emeryville, USA

Vaccine Research Program/Adjuvant Program responsibilities:
- Project leader of NVD's RSV vaccine project (Respiratory Syncytial Virus)
- Coordinator of preclinical activities on combined seasonal RSV-Influenza vaccine for elderly & high risk adults
- Responsible for defining and shaping the scope and strategy of NVD's adjuvant and vaccine delivery technologies including management of NVD's adjuvant portfolio, opportunity...

Head of Adjuvant Technologies and Alternative Deliveries, R&D

GlaxoSmithKline Biologicals
May 2001 - May 2006
Rixensart, Belgium

- Research Program Leader on Vaccine Formulation Development & Alternative Deliveries and in charge of biophysical characterization activities on adjuvanted vaccine

formulations.
- Coordination and follow-up of extramural contracts & collaboration agreements on new immunization strategies and innovative vaccine adjuvant, delivery or formulation technologies (e.g., co-delivery, mucosal, subcutaneous, intradermal immunization)
- Development and validation of vaccine and…

GSK Biologicals

- **Senior Project Leader 'Adolescent Vaccine Projects'**
  Jun 1998 - May 2001
  Rixensart, Belgium
  Major responsibilities:
  Project Management on Raw Material Traceability (RAMATRA) and vaccine projects in Late Development, e.g., Herpes Simplex Virus type 2, Hepatitis B, Streptococcus Pneumoniae and Enterotoxic Escherichia Coli (in collaboration with SBL Vaccines, Sweden)
- **New Biotech Vaccine Development and QC-QA Manager**
  Feb 1995 - May 1998
  Rixensart, Belgium
  Major responsibilities (3 direct reports; 6 technicians):

  - Management and coordination of vaccine product development, optimization as well as validation of analytical methods in accordance with regulatory requirements or guidelines and vaccine marketing constraints
  - Budget management of all activities related to QC assay development
  - Transfer from R&D and further development of new QC-relevant characterization techniques on new vaccine candidates (e.g., HSV-2 vaccine, Lyme disease vaccine); contacts with national/international regulatory and health authorities (e.g., FDA, NIBSC, IHE, WHO,…) on technical dossiers; active participation in pre-IND meetings

  https://be.linkedin.com/in/geertvandenbossche